Download Citation
Article Source:
Dacomitinib, an Irreversible Pan-ErbB Inhibitor Significantly Abrogates Growth in Head and Neck Cancer Models That Exhibit Low Response to Cetuximab
Ather F,
Hamidi H,
Fejzo MS,
Letrent S,
Finn RS,
et al.
(2013)
Dacomitinib, an Irreversible Pan-ErbB Inhibitor Significantly Abrogates Growth in Head and Neck Cancer Models That Exhibit Low Response to Cetuximab.
PLOS ONE 8(2): e56112.
https://doi.org/10.1371/journal.pone.0056112